Effectiveness of plant-based protein powder recipes to muscle mass and health in elderly sarcopenia subjects

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20231101005

Enrollment

106

Registered

2023-11-01

Start date

2023-10-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia patients (age above 60 year old) Plant-based protein powder, sarcopenia

Interventions

Sarcopenia patients receive protein powder 60-90 g per day (0.8-1.2 g/kg/day) for 3 months with exercise. ,Sarcopenia patients will exercise alone.

Experimental Dietary Supplement,No Intervention No treatment

Protein group,Control group

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Elderly (age above 60) who have sarcopenia (The Asian Working Group for Sarcopenia (AWGS) 2019; 1.1. Handgrip strength less than 28 kg in male or less than 18 kg in female 1.2. Muscle mass measured by Bioelectrical impedence analysis (BIA) <7.0 kg/m2 in male or <5.7 kg/m2 in female 1.3. Calf circumference less than 34 cm in male or less than 33 cm in female 1.4. SARC-F (Strength, assistance with walking, rising from a chair, climbing stairs, and falls) >4

Exclusion criteria

Exclusion criteria: 1. Abnormal vital sign (Temp > 37.5 , pulse > 100 beat/min, Blood pressure < 90/60 or > 160/90 mmHg at rest) 2. history of Diabetes Mellitus 3. Abnormal liver enzyme 4. Uncontrollable hyperlipidemia 5. Glomerular Filtration Rate; GFR less than 60% 6. Has nephrotic syndrome 7. Receive anticoagulant 8. History of cancer 9. Dementia patients 10. Heart disease or have pacemaker 11. Abnormality of blood chemistry - Hemoglobin < 8 g/dL - White blood cells < 4,000 per cu. mm. - Platelets < 100,000 per cu. mm. - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 1.5 times the upper limit of normal - Creatinine more than 1.8 times the upper limit of normal, and - Abnormal urine analysis (protein positive in urine > 2+)

Design outcomes

Primary

Measure	Time frame
muscle mass 0 and at the end of 3 months Dual energy X-ray adsorptiometry ,muscle mass at 0, 1 month, 2 months, 3 months and 6 months Bioelectrical impedance	—

Secondary

Measure	Time frame
physical performance at 0, 1 month, 2 months, 3 months and 6 months 6-meters walk, 5-time chair stand test, time up and go test,calf circumference at 0, 1 month, 2 months, 3 months and 6 months measure calf circumference ,SARC-F (Strength, assistance with walking, rising from a chair, climbing stairs, and falls) at 0 and 3 months questionares,EQ-5D at 0 and 3 months questionares,Blood chemistry at 0 and 3 months Complete blood count, serum protein, albumin and globulin, glucose, calcium, magnesium, electrolyte,safety profile at 0, 1 month, 2 months, 3 months BUN, creatinine, liver enzyme (AST, ALT),Urine metabolome at 0, 1 month, 2 months, 3 months and 6 months mass spectrometer	—

Measure

Time frame

physical performance at 0, 1 month, 2 months, 3 months and 6 months 6-meters walk, 5-time chair stand test, time up and go test,calf circumference at 0, 1 month, 2 months, 3 months and 6 months measure calf circumference ,SARC-F (Strength, assistance with walking, rising from a chair, climbing stairs, and falls) at 0 and 3 months questionares,EQ-5D at 0 and 3 months questionares,Blood chemistry at 0 and 3 months Complete blood count, serum protein, albumin and globulin, glucose, calcium, magnesium, electrolyte,safety profile at 0, 1 month, 2 months, 3 months BUN, creatinine, liver enzyme (AST, ALT),Urine metabolome at 0, 1 month, 2 months, 3 months and 6 months mass spectrometer

—

Countries

Thailand

Contacts

Public ContactSaranyapin Potikanond

Chiang Mai University

spotikanond@gmail.com66888262453

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026